Fresh analysis suggests that patients who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who stop traditional diet and exercise plans.
Findings released in a major health publication shows that while obese people can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing such treatments must be aware of the danger of rapid rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
This pace of regain suggests a return to original weight within about one and a half years.
Comparing Approaches
The study, which reviewed dozens of trials involving thousands of participants, contrasted the effects of these new drugs with older methods.
Scientists note that people who shed pounds through dieting typically experience a slower weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Doctors suggest the mode of action of the drugs accounts for the amplified regain.
These medications copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
The NHS suggest the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals say that, given the likelihood of relapse, the treatment should be considered long-term.
This perspective is supported by pharmaceutical companies, who say that the results "underscore the long-term nature of obesity," comparing it to managing diseases like hypertension.
User Experiences
Users who have discontinued the medication describe a intense return of cravings.
"It felt as if a trigger activating and you become ravenous," said an individual.
The struggle is compounded if individuals have not established lasting dietary or behavioural changes during therapy.
Widespread Adoption
Survey data show that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while these medications are powerful tools for weight loss, they are not a standalone cure and maintained weight loss hinges on combined lifestyle changes.
